Skin Cancer Vaccine: Moderna and Merck's Personalized mRNA Therapy Cuts Melanoma Recurrence by Nearly Half

Melanoma, one of the most dangerous and aggressive forms of skin cancer, is seeing a monumental shift in therapeutic research. A revolutionary personalized mRNA therapy jointly developed by pharmaceutical giants Moderna and Merck is generating immense hope for high-risk patients. Hailed as a potential game-changer in modern oncology, this individualized treatment approach aims to train the human immune system to hunt down and destroy cancer cells with unprecedented precision.How the Personalized mRNA Vaccine WorksUnlike conventional vaccines administered to healthy individuals to prevent infectious diseases, this innovative therapy—scientifically named Intismeeran Autogene (4157/V940)—is entirely customized.